Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + neratinib + trastuzumab
- Development stage
- Phase 2
- Lead developer
- Puma Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intramuscular, Intravenous
01
Overview
A triplet combination therapy consisting of fulvestrant (a selective estrogen receptor degrader), neratinib (an irreversible pan-HER tyrosine kinase inhibitor), and trastuzumab (a HER2-targeting monoclonal antibody). This combination has shown efficacy in hormone receptor-positive, HER2-negative metastatic breast cancer harboring HER2 mutations, particularly in patients who have progressed on CDK4/6 inhibitors.
02
Targets
EGFR (Epidermal growth factor receptor)ER (Estrogen receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on fulvestrant + neratinib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + neratinib + trastuzumab.